Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis

Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis

Por: Alessia Fornoni, Junichiro Sageshima, Changli Wei, Sandra Merscher-Gomez, Robier Aguillon-Prada, Alexandra N. Jauregui, et al.  Science Translational Medicine June 2011,3:(85): 85ra46

Focal segmental glomerulosclerosis (FSGS) is a glomerular disease characterized by proteinuria, progression to end-stage renal disease, and recurrence of proteinuria after kidney transplantation in about one-third of patients. It has been suggested that rituximab might treat recurrent FSGS through an unknown mechanism